Society for Cardiovascular Angiography and Interventions (SCAI) 2022 Scientific Sessions

Atlanta, Georgia, US 19 May 2022 - 22 May 2022

Paclitaxel-coated devices in femoropopliteal artery revascularization: Mortality risk fears unfounded?

10 Jun 2022 by

Among patients undergoing femoropopliteal artery revascularization, mortality risk was not affected regardless of whether they were treated with drug-coated devices (DCDs) or non–drug-coated devices (NDCDs), according to updated results of the SAFE-PAD* study presented at SCAI 2022.

Paclitaxel-coated devices in femoropopliteal artery revascularization: Mortality risk fears unfounded?

10 Jun 2022

Clopidogrel monotherapy trumps aspirin monotherapy in reducing CV events post-PCI

03 Jun 2022 by

One year after undergoing percutaneous coronary intervention (PCI), high-risk patients on clopidogrel monotherapy have a reduced risk of multiple cardiovascular (CV) outcomes compared with those on aspirin monotherapy, according to a study presented at SCAI 2022.

Clopidogrel monotherapy trumps aspirin monotherapy in reducing CV events post-PCI

03 Jun 2022

IVL maintains superiority over PTA at 1 year for peripheral artery calcification

03 Jun 2022 by

In the Disrupt PAD III trial, superior primary patency (PP) was achieved at 1 year with intravascular lithotripsy (IVL) plus a drug-coated balloon (DCB) compared with percutaneous transluminal angioplasty (PTA) + DCB, confirming the consistent safety and efficacy of IVL to facilitate a durable approach for individuals with heavily calcified femoropopliteal arteries largely without stent requirement.

IVL maintains superiority over PTA at 1 year for peripheral artery calcification

03 Jun 2022

Harmony TPV continues to show safety, efficacy for recipients at 1 year

02 Jun 2022 by

In an expanded analysis presented at SCAI 2022, recipients of the Harmony transcatheter pulmonary valve (TPV) continued to demonstrate favourable clinical and haemodynamic outcomes, confirming previous results and showing continued device success across studies and valve types at 1 year and beyond.

Harmony TPV continues to show safety, efficacy for recipients at 1 year

02 Jun 2022